Mimi Phan, MD
Pulmonary Disease · Houston, TXNPI 1093035610
Payments from drug & device makers
Across 368 payments — averaging $23.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$2K
- GSK$980
- Electromed, Inc.$904
- Sanofi$799
- Mylan Specialty L.p.$581
- Regeneron Healthcare Solutions, Inc.$526
- plus $3K from 30 others
What the payments were for
- Food & beverage$8,50899%
- Education$851%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 65 | $1,656 |
| GSK | 54 | $980 |
| Electromed, Inc. | 69 | $904 |
| Sanofi | 15 | $799 |
| Mylan Specialty L.p. | 23 | $581 |
| Regeneron Healthcare Solutions, Inc. | 22 | $526 |
| Amgen | 14 | $342 |
| Insmed, Inc. | 12 | $243 |
| AbbVie(2 entities) | 7 | $208 |
| Revance Therapeutics, Inc. | 4 | $207 |
| Verona Pharma, Inc. | 7 | $174 |
| Genentech USA, Inc. | 3 | $172 |
| Inspire Medical Systems, Inc. | 1 | $148 |
| Pulmonx Corporation | 1 | $146 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $144 |
| Boehringer Ingelheim | 7 | $140 |
| Optinose US, Inc. | 6 | $140 |
| Johnson & Johnson | 6 | $107 |
| Philips North America LLC | 6 | $107 |
| Inogen, Inc. | 4 | $102 |
| Shionogi Inc | 5 | $98 |
| Merck | 7 | $97 |
| Octapharma USA, Inc. | 1 | $78 |
| Grifols USA, LLC | 3 | $70 |
| Sunovion Pharmaceuticals Inc. | 5 | $69 |
| Viatris Specialty LLC | 2 | $66 |
| United Therapeutics Corporation | 2 | $42 |
| Paratek Pharmaceuticals, Inc. | 2 | $41 |
| Ambu Inc. | 1 | $39 |
| Tactile Systems Technology Inc | 1 | $36 |
| Novartis | 2 | $27 |
| Biofrontera Inc. | 1 | $23 |
| Liquidia Technologies, Inc. | 1 | $23 |
| Teva Pharmaceuticals USA, Inc. | 1 | $21 |
| Arbor Pharmaceuticals, Inc. | 1 | $20 |
| Kaleo, Inc. | 1 | $18 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- DUPIXENT$368
- Inspire$148
- CHARTIS CATHETER$146
- ZEPHYR DELIVERY CATHETER$146
- ZEPHYR ENDOBRONCHIAL VALVE$146
- PULMONX CHARTIS TABLET CONSOLE$146
- TEZSPIRE$125
- BREZTRI$125
- AIRSUPRA$114
- BOTOX$112
How this compares
$8,593 in reported general payments places this provider in the 65th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 28 | $359,873 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 226 | $183,840 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 66 | $59,946 |
| Dupixent PenDupilumab | 13 | $53,666 |
| Spiriva RespimatTiotropium Bromide | 57 | $37,978 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 56 | $24,818 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 26 | $13,745 |
| Breo ElliptaFluticasone/Vilanterol | 21 | $11,562 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 336 | $5,834 |
| Roflumilast | 52 | $4,487 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 25 | $3,263 |
| Azelastine Hcl | 109 | $2,393 |
| BreynaBudesonide/Formoterol Fumarate | 19 | $2,132 |
| Wixela InhubFluticasone Propion/Salmeterol | 30 | $2,074 |
| Levocetirizine Dihydrochloride | 126 | $1,399 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $140 | $411,597111 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta | $980 | $220,220303 claims |
| AstraZenecaBreztri Aerosphere | $1,656 | $59,94666 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Houston
- Ivan RosasHouston$13.8M
- Nicola HananiaHouston$2.2M
- Sandeep SahayHouston$2.1M
- Zeenat SafdarHouston$1.7M
- Howard HuangHouston$1.3M
- Dileep PuppalaHouston$1.1M
- Sandeep GuptaHouston$1.1M
- Joseph VaronHouston$1.1M
- Bela PatelHouston$974K
- Roberto CasalHouston$865K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.